摘要
阿托伐他汀是目前临床上广泛使用的口服调脂药,主要通过降低甘油三酯和低密度脂蛋白发挥作用,但其疗效及个体差异大。广谱调脂药阿昔莫司主要降低总胆固醇,提高高密度脂蛋白水平,但副作用较明显,限制其临床使用。用单一调脂药临床效果不明显,而联用他汀类和烟酸类调脂药效果优于单用。本文对阿托伐他汀与阿昔莫司联合应用的临床药理学特征进行综述。
Atorvastatin is widely used as an oral blood lipid -lowering drug, which can reduce the triglyceride and low density lipoprotein. However, it has obvious individual difference. Aeipimox is another kind of broad spectrum lipid - lowering drug, it mainly reduce total cholester- ol, improving the level of high density lipoprotein. But its side effect is very apparent which make it be limited to some extent. Many domestic and foreign research confirmed that a single lipid -lowering drug was not obvious on lipid profile. Many research also showed that atorvastatin co- administrated with acipimox offered better targeted therapy and was well tolerated with proper monitoring in hyperlipoidemia patients. This article summarizes the research progress of atorvastatin coadministrated with acipimox on pharmacology and pharmaeokinetics based on some previous achievements.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2013年第5期392-394,共3页
The Chinese Journal of Clinical Pharmacology
基金
国家十二五科技重大专项基金资助项目(2011ZX 09302-007-03)
